Parkinson’s Disease Treatment Market By Treatment Type (Surgical Treatments {Deep Brain Stimulation (DBS) and Lesioning procedures}, Non-Surgical Treatments {Medications [Dopaminergic medications, MAO-B inhibitors, COMT inhibitors, Anticholinergics, and Amantadine] and Supportive Therapies [Physical therapy, Occupational therapy, and Speech therapy]}, and Others), By Route of Administration (Oral, Injectable, Transdermal, and Inhalable), By Disease Stage (Stage 1, Stage 2, Stage 3, Stage 4, and Stage 5), and By End-User (Hospitals, Specialty clinics, Home care settings, and Rehabilitation centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Parkinson’s Disease Treatment market accounted for USD 6.4 Billion in 2024 and is expected to reach USD 18.6 Billion by 2035, growing at a CAGR of around 10.2% between 2025 and 2035. The Parkinson's Disease Treatment Market encompasses all treatment options available, including therapies, medications, medical equipment, and gadgets used to treat Parkinson's disease, a neurological illness. This market comprises dopaminergic medications, including levodopa and dopamine agonists, non-dopaminergic drugs, surgery, deep brain stimulation, and supportive treatments. The overall incidence of the disease is increasing, and therefore the market is experiencing growth on the back of enhanced research solutions, technology, and diagnostic rates. Stakeholders are committed to developing new goods to improve the patient's well-being, demonstrating the market's development.

Report Scope:

Market Dynamics

Expanding healthcare infrastructure increases access to treatment services globally.

The rise of the Parkinson's disease treatment market is linked to several reasons, including rising disease incidence rates, the development of new medications, and the development of personalized therapy. With increasing progression in age, the requirement for efficient treatments shifts, thus leading to the development of new therapies, including neuroprotective agents and techniques for deep brain stimulation. There is increased awareness of the disease and advocacy efforts to secure money for additional studies. For instance, a National Institute of Neurological Disorders and Stroke (NINDS) report reveals that the number of Parkinsonism patients is over 0.9 million in the United States of America, highlighting the necessity of expanding health care and treatment services. This demonstrates that educational institutions are engaged in research and development, contributing to market growth.

Technological innovations improve treatment modalities and patient outcomes significantly.

The Parkinson’s disease treatment market is driven by several factors. The number of Parkinson's disease patients is progressively increasing as the aged population grows. The identification of the neuropathological characteristics of the disease has resulted in an increased demand for effective therapies. Trends such as improved technological systems, new solutions for drug formulation, and fresh approaches to treatment delivery contribute to improved treatment outcomes. Further, advancing expenditure on research and development by pharmaceutical companies and biotechnology firms means new disease-modifying therapies are in development. Other crucial considerations include an increased understanding of Parkinson's disease-related syndromes among caregivers, officers, and patients, helping in the search for an early diagnosis. Moreover, telemedicine and mobile health apps, becoming components of digital health solutions, improve both patient monitoring and tailored patient care strategies, resulting in increased market demand.

Lack of effective cure focuses treatment on symptom relief.

Parkinson’s Disease Treatment Market has several challenges that affect its growth prospects. One of them is that curative therapies are uncommon, with the majority of treatments available focusing on symptom relief rather than illness cure. This limitation may prevent corporations from spending further on R&D, as most markets in this region continue to focus on symptom treatment rather than seeking a lasting cure. Additional characteristics of this condition, such as the diversity of disease symptoms and progression rates, make it challenging to treat and attain consistent outcomes for patients. Furthermore, the high cost of continued symptomatic treatments places a significant load on healthcare expenses, driving them higher, particularly in poor countries. These factors account for difficulties experienced in market growth and development of new Parkinson’s disease treatment products.

Development of biomarkers enables early diagnosis and personalized treatment.

The biomarker discovery for Parkinson’s Disease has potential in the therapeutics market by offering accurate diagnosis for early intervention. They found that early disease detection allows early interventions to slow disease progression and potentially enhance patient prognosis. Biomarkers also aid in the classification of patients based on certain illness characteristics that must be addressed for patients to receive tailored medication with greater efficacy and fewer adverse effects. The change toward personalized medicine improves the outcome and the costs of the treatments by eliminating guesswork in selecting therapies. Furthermore, the demand for new solutions for the older population boosts market capacity by encouraging investors to engage in research. The use of biomarkers in Parkinson's disease management implies significant changes in the lower and higher therapy maps and could help patients have a better quality of life.

Patient-centric approaches customize treatments based on individual genetic factors.

Parkinson’s Disease Treatment Market is very promising for the development of patient-centric strategies based on personal genetic predispositions. With scientific developments, early identification of genotypes that determine the disease course and responses to medications is vital. This customization increases the effectiveness of the therapy and reduces side effects, resulting in better patient outcomes. Moreover, the emphasis on precision medicine is growing, and multinational companies and biotech enterprises invest in genetic diagnostics and individualized treatment. Such a transition brings added value to developing therapeutic approaches based on genetic data by positioning innovators as market players with competitive advantages over the Parkinson’s market. This approach enhances patient compliance and satisfaction and speaks to the feasibility of the strategy, which in turn makes this line a rich one for growth and investment.

Industry Experts Opinion

 “Innovation is at the core of our approach to translational research and drug discovery at Lundbeck and I'm thrilled that we are partnering with MJFF to bring therapeutic solutions for patients in need. Research in synucleinopathies, including Parkinson’s disease and multiple system atrophy, is rapidly evolving and the unmet need for new therapies, diagnostics, and disease relevant biomarkers has never been greater. We continue to be committed to our mission to restore brain health for the millions of people living with brain diseases.”

• Tarek Samad, PhD, SVP, Head of Research at Lundbeck.

Segment Analysis

Based on the treatment type, the Parkinson’s Disease Treatment Market is classified into Surgical Treatments, Non-Surgical Treatments, and Others. The largest segment in the Parkinson’s Disease Treatment Market is Non-Surgical Treatments. The drugs that are in this category include Levodopa, Dopamine agonists, and MAO B inhibitors, which are basic in managing symptoms and enhancing the quality of lives of patients. People prefer to avoid anything that requires incisions, and this explains the rising usage of drugs. Technological improvements in drug compounds and techniques of administration support this trend. Furthermore, because non-surgical procedures are more accessible and have lower risk factors than surgeries, they remain the primary choice of both patients and physicians.

Based on the route of administration, the Parkinson’s Disease Treatment Market is classified into Oral, Injectable, Transdermal, and Inhalable.  Oral is the dominant route of administration in the Parkinson’s Disease Treatment Market. This choice stems from the benefits of using oral medications such as levodopa and dopamine agonists, among others, to treat symptoms. Patients prefer liquid and suspension doses because they can be taken in divided amounts and are easier to administer. Furthermore, the oral route is less expensive than the injectable or inhalable routes. Thus, patients and caregivers prefer it for Parkinson's disease.

Regional Analysis

North America is the leading region in the Parkinson’s Disease Treatment market because of progress in medications, technologies of neuromodulation therapy, and support care. The region places a high value on research and development leading to the creation of new medicines to manage symptoms and illness progression. Furthermore, awareness of Parkinson's disease has increased, and incidence rates are rising, expanding the market for disclosed therapeutic alternatives. Public-private collaborations between healthcare leaders and research institutes ensure that patients benefit from innovative care solutions, and support groups and educational program developers increase patient treatment and quality of life. Different trends emerge over time, such as telehealth and personalized care, and these are likely to define treatment disciplines across markets.

The European Parkinson's Disease Treatment Market is growing owing to advances in research, increased healthcare spending, and an aging population. Leading nations, particularly Germany, France, and the United Kingdom, are investing in advanced therapies that include medication and cap contact therapy. In terms of drug approval and the introduction of digital health choices into patient care, treatment compliance benefits from existing regulations. The market is highly advanced, with a focus on patient-centered solutions as healthcare providers construct personalized treatment plans for each patient. Moreover, the government and other stakeholder organizations are promoting more collaborative research programs aimed at discovering alternative treatments. Parkinson’s care awareness and advocacy are playing a major role in boosting access to and support services in regional Europe, propelling the broader European region to the forefront of global Parkinson’s treatment.

Competitive Landscape

The Parkinson’s Disease treatment market is witnessing intense participation of major industry players like AbbVie, Bristol-Myers Squibb, and Teva Pharmaceutical Industries. AbbVie has recently improved its approach to its focus on JAK with its new treatments that target movement. Teva has introduced improved formulations of existing medications, while Lundbeck has attempted to develop novel compounds that target nonmotor problems. Furthermore, the business has success in expanding its pipeline, with clinical studies of Neurocrine Biosciences experimental medications yielding encouraging results. There is also a rise in both cooperation and affiliations, such as Roche working with biotech companies to improve treatment plans, discussions indicating that the market is active and young.

Parkinson’s Disease Treatment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In September 2024, AbbVie announced positive topline results from its Phase 3 TEMPO-1 trial, showing that Tavapadon was effective as a monotherapy for Parkinson's Disease. The trial's outcomes indicated potential improvements in treatment options for patients, highlighting Tavapadon's role in managing symptoms of the disorder.
• In September 2024, Medtronic published its pioneering manuscript on the ADAPT-PD clinical trial methods, setting new standards in Parkinson's disease research. This innovative approach enhanced the understanding of treatment efficacy and improved patient outcomes in managing the disease.

Report Coverage:

By Treatment Type

• Surgical Treatments
  • Deep Brain Stimulation (DBS)
  • Lesioning procedures
  • Others
• Non-Surgical Treatments
  • Medications
    • Dopaminergic medications
    • MAO-B inhibitors
    • COMT inhibitors
    • Anticholinergics
    • Amantadine
    • Others
  • Supportive Therapies
    • Physical therapy
    • Occupational therapy
    • Speech therapy
    • Others

By Route of Administration

• Oral
• Injectable
• Transdermal
• Inhalation

By Disease Stage

• Stage 1
• Stage 2
• Stage 3
• Stage 4
• Stage 5

By End User

• Hospitals
• Specialty clinics
• Home care settings
• Rehabilitation centers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• AbbVie Inc.
• Bristol-Myers Squibb
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc
• Lundbeck A/S
• Novartis AG
• Amgen Inc.
• Sanofi S.A.
• Neurocrine Biosciences, Inc.
• Roche Holding AG
• Acorda Therapeutics, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Zambon S.p.A.
• Medtronic plc
• UCB S.A.

Frequently Asked Questions (FAQs)